Skip to main content
Defiance International

Published study records

Study records for CBL research preparation

Study records describe published research and its limitations. They do not establish efficacy, safety, or suitability for any use.

Study record counts

554 study records.

71 evidence-verified · 381 citation-verified · 98 identifier-confirmed · 4 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • In vitro: 49
  • In vivo/preclinical: 187
  • Review/meta-analysis: 51
  • Other: 0
Filter study recordsReset filters

Filtered results

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Retraction Note: Cerebrolysin Attenuates Exacerbation of Neuropathic Pain, Blood-Spinal Cord Barrier Breakdown and Cord Pathology Following Chronic Intoxication of Engineered Ag, Cu or Al (50-60 nm) Nanoparticles.

Neurochemical research · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-09: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Cerebrolysin and Risk of Hemorrhagic Transformation: A Pooled Analysis of Recent Studies.

Journal of clinical neurology (Seoul, Korea) · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-09: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Editorial Expression of Concern: Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin.

Acta neuropathologica · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-09: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Adjunctive Cerebrolysin therapy following mechanical thrombectomy for acute basilar artery occlusion: a case report.

Journal of medicine and life · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-09: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Retraction Note to: Timed Release of Cerebrolysin Using Drug-Loaded Titanate Nanospheres Reduces Brain Pathology and Improves Behavioral Functions in Parkinson's Disease.

Molecular neurobiology · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-09: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Cerebrolysin as an adjunct to speech-language therapy in post-stroke Wernicke's aphasia: a case report.

Journal of medicine and life · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-09: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Adjunctive Cerebrolysin therapy following mechanical thrombectomy for tandem right internal carotid artery and middle cerebral artery occlusion with residual post-procedural perfusion deficit: a case report.

Journal of medicine and life · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-10-22: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2026

Longitudinal Serum and Cerebrospinal Fluid S100B Concentrations After Aneurysmal Subarachnoid Hemorrhage: An Exploratory Comparison of Historical Cohorts With and Without Cerebrolysin Exposure.

Journal of clinical medicine · 2026

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-11-16: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: DOI confirmed at Crossref

  • 2025

Cerebrolysin, Hemorrhagic Transformation, and Anticoagulation Timing after Reperfusion Therapy in Stroke: Secondary Analysis of the CEREHETIS Trial

2025

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

DOI confirmed at Crossref. The DOI shown was confirmed at Crossref on 2026-09-09: Crossref held a registration for this identifier. This check confirms the identifier only, not the kind of work, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2025

Surgical excision of cerebral glioma and multimodal treatment including Cerebrolysin: a case report.

Journal of medicine and life · 2025

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-09: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2025

Correction to: Sonic Hedgehog Signaling Pathway Mediates Cerebrolysin-Improved Neurological Function After Stroke.

Stroke · 2025

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-09: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type not established · Verification: PMID confirmed at PubMed

  • 2025

Therapeutic Potential of Porcine Brain-Derived Peptide Mixture (PBDP) in Alzheimer's Disease: An Exploratory Study on Quantitative Electroencephalography (qEEG) Changes.

Neuropsychiatric disease and treatment · 2025

Study scale: Not reported in the declared source.

Bibliographic details only: Open source record

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

PMID confirmed at PubMed. The PMID shown was confirmed at PubMed on 2026-09-14: PubMed held a record under this identifier. This check confirms the identifier only, not the study type, the findings, or any relevance to a chemical sequence. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.